WO2003101390A3 - Endobronchial delivery of antibiotic in individuals with impaired lung tissue or lung function - Google Patents

Endobronchial delivery of antibiotic in individuals with impaired lung tissue or lung function Download PDF

Info

Publication number
WO2003101390A3
WO2003101390A3 PCT/US2003/017151 US0317151W WO03101390A3 WO 2003101390 A3 WO2003101390 A3 WO 2003101390A3 US 0317151 W US0317151 W US 0317151W WO 03101390 A3 WO03101390 A3 WO 03101390A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibiotic
individuals
lung
aeruginosa
Prior art date
Application number
PCT/US2003/017151
Other languages
French (fr)
Other versions
WO2003101390A2 (en
Inventor
Bonnie Ramsey
Ronald Gibson
Original Assignee
Childrens Hospital And Regiona
Bonnie Ramsey
Ronald Gibson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital And Regiona, Bonnie Ramsey, Ronald Gibson filed Critical Childrens Hospital And Regiona
Priority to AU2003238846A priority Critical patent/AU2003238846A1/en
Publication of WO2003101390A2 publication Critical patent/WO2003101390A2/en
Publication of WO2003101390A3 publication Critical patent/WO2003101390A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods for producing a significant anti-P. aeruginosa effect in a cystic fibrosis patient 6 years of age or younger that presents with early P. aeruginosa infection are disclosed. Such methods involve endobronchial administration of an aerosolized tobramycin formulation, wherein said formulation is administered as a monotherapy for a period of about one month. In addition, methods for selecting a cystic fibrosis patient 6 years of age or younger that my benefit from the claimed methods, as well as methods for monitoring anti- P. aeruginosa aerosol antibiotic treatment outcome in such patients, are disclosed.
PCT/US2003/017151 2002-05-31 2003-05-30 Endobronchial delivery of antibiotic in individuals with impaired lung tissue or lung function WO2003101390A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003238846A AU2003238846A1 (en) 2002-05-31 2003-05-30 Endobronchial delivery of antibiotic in individuals with impaired lung tissue or lung function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38472302P 2002-05-31 2002-05-31
US60/384,723 2002-05-31

Publications (2)

Publication Number Publication Date
WO2003101390A2 WO2003101390A2 (en) 2003-12-11
WO2003101390A3 true WO2003101390A3 (en) 2004-08-12

Family

ID=29712083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017151 WO2003101390A2 (en) 2002-05-31 2003-05-30 Endobronchial delivery of antibiotic in individuals with impaired lung tissue or lung function

Country Status (2)

Country Link
AU (1) AU2003238846A1 (en)
WO (1) WO2003101390A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6387886B1 (en) * 1998-12-17 2002-05-14 Chiron Corporation Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6387886B1 (en) * 1998-12-17 2002-05-14 Chiron Corporation Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
O'RIORDAN T.G. ET AL.: "Effect of nebulizer configuration on delivery of aerosolized tobramycin", JOURNAL OF AEROSOL MEDICINE, vol. 10, no. 1, 1997, pages 13 - 23, XP001095886 *

Also Published As

Publication number Publication date
WO2003101390A2 (en) 2003-12-11
AU2003238846A1 (en) 2003-12-19
AU2003238846A8 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
EP2186508A3 (en) Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
EP1513493B8 (en) Analgesics
RU2007101906A (en) METHODS FOR TREATING ENDOBRONCHIAL DISEASES
EP1586338A3 (en) The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
WO2004028570A3 (en) A method for treating severe tinnitus
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
EP3268010B1 (en) Compositions comprising acidified nitrite, an iron chelator and an antibiotic agent for use in the treatment of bacterial infections
CA2446435A1 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003041686A3 (en) Improved therapy for topical diseases
WO2005058935A3 (en) Aqueous suspensions of ciclesonide for nebulisation
WO2003011327A3 (en) Secretin for the treatment of asthma
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2004017913A3 (en) Arginine silicate inositol complex and use thereof
WO1999040883A3 (en) Compositions and methods for the treatment of cystic fibrosis
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
CA2290446A1 (en) Method and compositions for administering taxanes orally to human patients
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
WO2002069979A3 (en) Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
WO2005004838A8 (en) Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof
WO2003101390A3 (en) Endobronchial delivery of antibiotic in individuals with impaired lung tissue or lung function
EP1393738A4 (en) Drugs for diabetes
Kramer et al. Unusual complication of nasal CPAP: subcutaneous emphysema following facial trauma
EP1270015A3 (en) A complex comprising OCIF and Polysaccharide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP